According to Ou et al., the overexpression of ST6Gal-1 attenuates the sensitivity of ovarian cancer cells to several anticancer drugs, including paclitaxel, Adriamycin, and the FGFR1 inhibitor, signed as PD173074 [129]. Here, ST6GAL1 is linked to ovarian carcinoma.